Apellis Pharmaceuticals Quarterly Balance Sheets Chart
Quarterly
|
Annual
Apellis Pharmaceuticals Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||||||||||||||
| current assets: | ||||||||||||||||||||||||||||||||
| cash and cash equivalents | 370,036,000 | 358,393,000 | 411,290,000 | 396,864,000 | 360,087,000 | 325,923,000 | 351,185,000 | 452,414,000 | 616,259,000 | 765,083,000 | 551,801,000 | 584,189,000 | 604,489,000 | 633,456,000 | 640,192,000 | 283,745,000 | 270,764,000 | 265,435,000 | 565,779,000 | 415,560,000 | 317,348,000 | 417,881,000 | 351,985,085 | 433,994,644 | 289,128,569 | 288,246,706 | 176,267,666 | 220,640,818 | 253,839,540 | 152,930,977 | 175,643,529 | 13,135,848 |
| accounts receivable | 214,131,000 | 235,246,000 | 264,926,000 | 279,011,000 | 304,433,000 | 267,837,000 | 206,442,000 | 169,258,000 | 110,913,000 | 31,505,000 | 7,727,000 | 8,091,000 | 7,518,000 | 6,330,000 | 10,103,000 | 3,522,000 | 719,000 | |||||||||||||||
| inventory | 121,000,000 | 82,468,000 | 81,404,000 | 121,058,000 | 152,772,000 | 161,283,000 | 146,362,000 | 98,545,000 | 103,216,000 | 85,484,000 | 85,714,000 | 59,753,000 | 48,451,000 | 32,850,000 | 16,286,000 | 1,677,000 | 3,731,000 | |||||||||||||||
| prepaid assets | 29,171,000 | 37,104,000 | 18,368,000 | 23,809,000 | 28,971,000 | 43,163,000 | 38,820,000 | 44,617,000 | 34,404,000 | 36,559,000 | 36,350,000 | 30,356,000 | 21,478,000 | 24,534,000 | 24,868,000 | 17,374,000 | 18,866,000 | 17,203,000 | 11,400,000 | 11,299,000 | 17,925,000 | 22,806,000 | 19,802,008 | 14,742,698 | 13,977,215 | 20,509,948 | 24,333,851 | 16,846,183 | 10,857,287 | 8,121,602 | 5,059,593 | |
| restricted cash | 1,430,000 | 1,434,000 | 1,322,000 | 1,373,000 | 1,339,000 | 1,103,000 | 1,114,000 | 1,086,000 | 1,085,000 | 1,275,000 | 1,273,000 | 1,259,000 | 1,266,000 | 1,558,000 | 1,563,000 | 1,563,000 | 1,572,000 | 1,552,000 | 1,266,000 | 1,255,000 | 1,248,000 | 1,016,000 | ||||||||||
| other current assets | 19,842,000 | 13,073,000 | 11,644,000 | 11,782,000 | 12,372,000 | 12,119,000 | 22,408,000 | 30,847,000 | 26,809,000 | 34,349,000 | 36,658,000 | 23,925,000 | 28,460,000 | 73,412,000 | 70,677,000 | 20,980,000 | 31,228,000 | 31,198,000 | 26,878,000 | 1,637,000 | 1,828,000 | 1,891,000 | 1,307,591 | 2,457,530 | 3,355,995 | 15,570 | 364,113 | 81,532 | 7,695 | 205,713 | 14,823 | 3,653,520 |
| total current assets | 755,610,000 | 727,718,000 | 788,954,000 | 833,897,000 | 859,974,000 | 811,428,000 | 766,331,000 | 796,767,000 | 892,686,000 | 954,255,000 | 719,523,000 | 831,937,000 | 959,969,000 | 1,103,982,000 | 824,047,000 | 475,427,000 | 655,126,000 | 773,625,000 | 917,192,000 | 742,349,000 | 853,825,000 | 672,407,000 | 373,094,684 | 451,194,872 | 308,412,717 | 310,527,863 | 202,439,221 | 238,932,792 | 266,701,518 | 163,086,857 | 182,015,306 | 19,032,933 |
| non-current assets: | ||||||||||||||||||||||||||||||||
| right-of-use assets | 14,637,000 | 15,251,000 | 16,083,000 | 17,060,000 | 16,321,000 | 14,994,000 | 16,745,000 | 15,484,000 | 16,726,000 | 17,854,000 | 18,747,000 | 19,522,000 | 20,755,000 | 19,972,000 | 19,901,000 | 20,930,000 | 21,939,000 | 22,518,000 | 17,719,000 | 18,545,000 | 12,959,000 | 13,715,000 | 14,110,209 | 13,332,783 | 6,644,312 | 6,621,807 | ||||||
| property and equipment | 2,117,000 | 2,514,000 | 2,952,000 | 3,379,000 | 3,836,000 | 4,195,000 | 4,345,000 | 4,790,000 | 5,339,000 | 5,967,000 | 6,148,000 | 5,681,000 | 5,892,000 | 5,893,000 | 6,177,000 | 6,509,000 | 6,750,000 | 7,077,000 | 6,803,000 | 6,531,000 | 2,416,000 | 1,972,000 | 1,654,999 | 1,592,787 | 1,439,108 | 1,041,063 | ||||||
| long-term inventory | 48,128,000 | 60,652,000 | 75,713,000 | 46,080,000 | 23,021,000 | |||||||||||||||||||||||||||
| other assets | 898,000 | 1,150,000 | 1,349,000 | 1,450,000 | 1,330,000 | 1,313,000 | 1,309,000 | 1,175,000 | 827,000 | 793,000 | 15,799,000 | 15,752,000 | 15,882,000 | 16,007,000 | 31,640,000 | 22,823,000 | 16,097,000 | 6,909,000 | 18,855,000 | 909,000 | 906,000 | 845,000 | 385,088 | 236,515 | 207,873 | 162,345 | 1,094,338 | 212,979 | 116,150 | 116,150 | 116,150 | 108,350 |
| total assets | 821,390,000 | 807,285,000 | 885,051,000 | 901,866,000 | 904,482,000 | 831,930,000 | 788,730,000 | 818,216,000 | 915,578,000 | 978,869,000 | 760,217,000 | 872,892,000 | 1,002,498,000 | 1,145,854,000 | 881,765,000 | 525,689,000 | 699,912,000 | 810,129,000 | 960,569,000 | 768,334,000 | 870,106,000 | 688,939,000 | 389,244,980 | 466,356,957 | 316,704,010 | 318,353,078 | 203,533,559 | 239,145,771 | 266,817,668 | 163,203,007 | 182,131,456 | 19,141,283 |
| liabilities and stockholders’ equity | ||||||||||||||||||||||||||||||||
| current liabilities: | ||||||||||||||||||||||||||||||||
| accounts payable | 54,241,000 | 55,287,000 | 38,572,000 | 42,730,000 | 38,270,000 | 26,788,000 | 37,516,000 | 18,192,000 | 27,500,000 | 31,494,000 | 37,342,000 | 14,099,000 | 16,220,000 | 12,273,000 | 16,909,000 | 4,984,000 | 5,339,000 | 4,158,000 | 8,477,000 | 11,069,000 | 9,927,000 | 3,078,000 | 8,360,527 | 11,836,609 | 13,811,730 | 11,916,152 | 10,254,938 | 5,468,800 | 5,133,017 | 4,585,058 | 3,663,253 | 4,001,059 |
| accrued expenses | 138,999,000 | 116,146,000 | 140,184,000 | 139,835,000 | 122,781,000 | 101,399,000 | 127,806,000 | 117,089,000 | 97,716,000 | 71,251,000 | 95,139,000 | 79,778,000 | 89,419,000 | 105,272,000 | 103,239,000 | 69,847,000 | 134,303,000 | 69,398,000 | 111,935,000 | 60,766,000 | 45,399,000 | 44,930,000 | 54,782,951 | 30,431,607 | 20,229,694 | 7,342,601 | 5,103,002 | 10,565,640 | 5,121,178 | 2,709,801 | 2,890,705 | 2,936,885 |
| current portion of lease liabilities | 7,419,000 | 6,944,000 | 6,753,000 | 6,792,000 | 6,214,000 | 6,257,000 | ||||||||||||||||||||||||||
| total current liabilities | 200,659,000 | 178,377,000 | 185,509,000 | 191,260,000 | 169,168,000 | 215,291,000 | 247,593,000 | 185,630,000 | 174,837,000 | 138,644,000 | 167,610,000 | 115,446,000 | 126,793,000 | 124,769,000 | 131,847,000 | 94,237,000 | 157,787,000 | 83,670,000 | 128,327,000 | 75,273,000 | 57,990,000 | 50,740,000 | 65,752,819 | 44,572,363 | 35,591,073 | 20,386,473 | 17,024,607 | 16,034,440 | 10,254,195 | 7,294,859 | 6,553,958 | 6,937,944 |
| long-term liabilities: | ||||||||||||||||||||||||||||||||
| long-term credit facility | 360,535,000 | 360,001,000 | 359,489,000 | 358,982,000 | 364,025,000 | |||||||||||||||||||||||||||
| convertible senior notes | 93,500,000 | 93,421,000 | 93,341,000 | 93,263,000 | 93,186,000 | 93,109,000 | 93,033,000 | 92,957,000 | 92,883,000 | 92,809,000 | 92,736,000 | 92,663,000 | 189,313,000 | 189,168,000 | 189,024,000 | 189,610,000 | 386,471,000 | 386,152,000 | 358,830,000 | 353,769,000 | 348,842,000 | 144,561,000 | 142,566,851 | 140,614,523 | ||||||||
| lease liabilities | 8,313,000 | 9,186,000 | 10,201,000 | 11,411,000 | 11,085,000 | 9,770,000 | ||||||||||||||||||||||||||
| other liabilities | 2,078,000 | 2,084,000 | 7,972,000 | 9,829,000 | 2,691,000 | 2,658,000 | 2,312,000 | 946,000 | 429,000 | 347,000 | 1,938,000 | 1,569,000 | 1,208,000 | 250,000 | 250,000 | 234,932 | ||||||||||||||||
| total liabilities | 665,085,000 | 643,069,000 | 656,512,000 | 664,745,000 | 640,155,000 | 565,254,000 | 594,209,000 | 585,945,000 | 570,175,000 | 566,746,000 | 590,345,000 | 565,476,000 | 668,080,000 | 683,619,000 | 683,103,000 | 583,014,000 | 841,405,000 | 758,471,000 | 756,012,000 | 662,494,000 | 638,042,000 | 429,942,000 | 355,015,304 | 326,795,143 | 157,617,972 | 93,598,186 | 42,560,904 | 43,190,921 | 37,265,562 | 34,160,902 | 33,188,596 | |
| commitments and contingencies | ||||||||||||||||||||||||||||||||
| stockholders’ equity: | ||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized, and no shares issued and outstanding at june 30, 2025 and december 31, 2024 | ||||||||||||||||||||||||||||||||
| common stock | 12,000 | 12,000 | 12,000 | 12,000 | 12,000 | 12,000 | 12,000 | 12,000 | 12,000 | 12,000 | 11,000 | 11,000 | 11,000 | 11,000 | 10,000 | 9,000 | 8,000 | 8,000 | 8,000 | 8,000 | 8,000 | 7,000 | 6,393 | 6,387 | 6,367 | 6,322 | 5,628 | 5,624 | 5,615 | 5,042 | 5,033 | 847 |
| additional paid-in capital | 3,328,604,000 | 3,294,849,000 | 3,267,201,000 | 3,239,262,000 | 3,209,245,000 | 3,174,100,000 | 3,035,539,000 | 2,982,236,000 | 2,954,862,000 | 2,899,524,000 | 2,479,596,000 | 2,453,301,000 | 2,289,201,000 | 2,259,906,000 | 1,857,430,000 | 1,453,431,000 | 1,173,512,000 | 1,147,263,000 | 1,131,013,000 | 1,112,203,000 | 1,100,639,000 | 615,849,518 | 435,915,657 | |||||||||
| accumulated other comprehensive loss | -2,569,000 | -3,054,000 | -3,308,000 | -3,140,000 | -3,362,000 | -3,525,000 | -3,542,000 | -1,065,000 | -796,000 | -775,000 | -875,000 | -3,027,000 | -3,194,000 | -2,059,000 | -2,090,000 | -2,010,000 | -1,829,000 | -1,620,000 | -117,000 | -153,775 | -205,249 | -121,977 | -120,645 | -122,807 | ||||||||
| accumulated deficit | -3,169,742,000 | -3,127,591,000 | -3,035,366,000 | -2,999,013,000 | -2,941,568,000 | -2,903,911,000 | -2,837,488,000 | -2,748,912,000 | -2,608,675,000 | -2,486,638,000 | -2,308,860,000 | -2,142,869,000 | -1,951,600,000 | -1,795,623,000 | -1,656,688,000 | -1,508,755,000 | -1,313,184,000 | -1,093,993,000 | -926,347,000 | -1,004,612,000 | -868,912,000 | -750,295,000 | -581,472,460 | -468,255,037 | -398,430,378 | -327,340,214 | -276,765,847 | -240,306,373 | -204,334,259 | -170,999,957 | -149,263,653 | -131,007,757 |
| total stockholders’ equity | 156,305,000 | 164,216,000 | 228,539,000 | 237,121,000 | 264,327,000 | 266,676,000 | 194,521,000 | 232,271,000 | 345,403,000 | 412,123,000 | 169,872,000 | 307,416,000 | 334,418,000 | 462,235,000 | 198,662,000 | 12,203,339 | ||||||||||||||||
| total liabilities and stockholders’ equity | 821,390,000 | 807,285,000 | 885,051,000 | 901,866,000 | 904,482,000 | 831,930,000 | 788,730,000 | 818,216,000 | 915,578,000 | 978,869,000 | 760,217,000 | 872,892,000 | 1,002,498,000 | 1,145,854,000 | 881,765,000 | 19,141,283 | ||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized, and no shares issued and outstanding at march 31, 2025 and december 31, 2024 | ||||||||||||||||||||||||||||||||
| current portion of development liability | 77,287,000 | 75,830,000 | 44,610,000 | 43,769,000 | 30,071,000 | 29,504,000 | 16,146,000 | 15,842,000 | 2,664,000 | 7,584,000 | ||||||||||||||||||||||
| long-term development liability | 244,426,000 | 239,817,000 | 295,532,000 | 289,960,000 | 321,713,000 | 315,647,000 | 340,142,000 | 333,729,000 | 351,784,000 | 345,151,000 | ||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized and zero shares issued and outstanding at december 31, 2024 and 2023 | ||||||||||||||||||||||||||||||||
| deferred revenue | 1,903,000 | 1,903,000 | 3,560,000 | |||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized, and zero shares issued and outstanding at september 30, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized, and zero shares issued and outstanding at june 30, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized, and zero shares issued and outstanding at march 31, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||||||
| current portion of right-of-use liabilities | 6,441,000 | 5,739,000 | 5,852,000 | 5,828,000 | 5,625,000 | 5,423,000 | 5,312,000 | 4,560,000 | 4,115,000 | 3,685,000 | ||||||||||||||||||||||
| right-of-use liabilities | 11,454,000 | 10,880,000 | 12,066,000 | 13,233,000 | 14,352,000 | 15,287,000 | 16,676,000 | 16,690,000 | 17,081,000 | 15,217,000 | 11,255,257 | 5,243,491 | 5,566,811 | |||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized and zero shares issued and outstanding at december 31, 2023 and 2022 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized, and zero shares issued and outstanding at september 30, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized, and zero shares issued and outstanding at june 30, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized, and zero shares issued and outstanding at march 31, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||||||
| marketable securities | 124,364,000 | 248,307,000 | 331,842,000 | 60,358,000 | 146,566,000 | 328,246,000 | 458,237,000 | 311,869,000 | 312,598,000 | 515,476,000 | 228,813,000 | |||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized and zero shares issued and outstanding at december 31, 2022 and 2021 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized, and zero shares issued and outstanding at september 30, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized, and zero shares issued and outstanding at june 30, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized, and zero shares issued and outstanding at march 31, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||||||
| current portion of development derivative liability | 15,334,000 | 14,110,000 | 6,212,000 | 4,230,000 | ||||||||||||||||||||||||||||
| development derivative liability | 281,017,000 | 278,022,000 | 268,740,000 | 253,638,000 | 217,778,000 | 220,475,000 | 223,245,000 | 134,839,000 | 130,103,000 | 109,840,000 | 60,736,000 | |||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized and zero shares issued and outstanding at december 31, 2021 and 2020 | ||||||||||||||||||||||||||||||||
| liabilities and stockholders' equity | ||||||||||||||||||||||||||||||||
| current portion of right of use liabilities | 4,072,000 | 4,035,000 | 3,902,000 | 3,438,000 | 2,664,000 | 2,732,000 | 2,304,147 | 1,549,649 | 1,127,720 | |||||||||||||||||||||||
| operating lease liabilities | 18,150,000 | 19,125,000 | 19,909,000 | 15,674,000 | 10,735,000 | 11,396,000 | 11,856,634 | |||||||||||||||||||||||||
| stockholders' equity: | ||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized, and zero shares issued and outstanding at september 30, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||||||
| total stockholders' equity | -57,325,000 | -141,493,000 | 51,658,000 | 204,557,000 | 105,840,000 | 232,064,000 | 258,997,000 | 34,229,676 | 139,561,814 | 159,086,038 | 224,754,892 | 160,972,655 | 195,954,850 | 229,552,106 | 129,042,105 | 148,942,860 | ||||||||||||||||
| total liabilities and stockholders' equity | 525,689,000 | 699,912,000 | 810,129,000 | 960,569,000 | 768,334,000 | 870,106,000 | 688,939,000 | 389,244,980 | 466,356,957 | 316,704,010 | 318,353,078 | 203,533,559 | 239,145,771 | 266,817,668 | 163,203,007 | 182,131,456 | ||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized, and zero shares issued and outstanding at june 30, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized, and zero shares issued and outstanding at march 31, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000 shares authorized and zero shares issued and outstanding at december 31, 2020 and 2019 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10.0 million shares authorized, and zero shares issued and outstanding at september 30, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||||||
| accumulated other comprehensive income/ | -1,759,000 | 329,000 | 1,010,000 | |||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10.0 million shares authorized, and zero shares issued and outstanding at june 30, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10.0 million shares authorized, and zero shares issued and outstanding at march 31, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||||||
| additional paid in capital | 1,008,275,000 | 608,015,713 | 557,632,026 | 552,209,429 | 437,855,681 | 433,880,750 | 300,037,020 | 298,201,480 | 31,407,476 | |||||||||||||||||||||||
| current portion of long-term-debt | ||||||||||||||||||||||||||||||||
| current portion of operating lease liabilities | 2,609,341 | |||||||||||||||||||||||||||||||
| term loan facility | 20,270,032 | 20,143,217 | 20,015,568 | 19,806,944 | ||||||||||||||||||||||||||||
| promissory note | 6,693,408 | 6,673,970 | 6,655,193 | 6,636,449 | ||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized and zero shares issued and outstanding at december 31, 2018 and 2019 | ||||||||||||||||||||||||||||||||
| current portion of long-term debt | 1,666,667 | |||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized, and zero shares issued and outstanding at december 31, 2018 and september 30, 2019 | ||||||||||||||||||||||||||||||||
| refundable research and development credit | 1,950,938 | 1,755,639 | 1,473,591 | 1,364,259 | 1,996,996 | 1,828,565 | 1,297,361 | 2,243,565 | ||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized, and zero shares issued and outstanding at december 31, 2018 and june 30, 2019 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized, and zero shares issued and outstanding at december 31, 2018 and march 31, 2019 | ||||||||||||||||||||||||||||||||
| term loan facility, net of current portion | 18,722,321 | |||||||||||||||||||||||||||||||
| common stock warrant liability | 158,783 | 250,000 | 250,000 | 250,000 | 244,292 | |||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized and zero shares issued and outstanding at december 31, 2017 and 2018 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized, and zero shares issued and outstanding at december 31, 2017 and september 30, 2018 | ||||||||||||||||||||||||||||||||
| accumulated other comprehensive income | 339,942 | |||||||||||||||||||||||||||||||
| promissory note - related party | 6,618,150 | 6,600,475 | 6,583,402 | |||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized, and zero shares issued and outstanding at december 31, 2017 and june 30, 2018 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized, and zero shares issued and outstanding at december 31, 2017 and march 31, 2018 | ||||||||||||||||||||||||||||||||
| series a convertible preferred stock, 0.0001 par value; 2,670,000 shares authorized, issued and outstanding at december 31, 2016 and zero shares authorized, issued and outstanding at december 31, 2017 | ||||||||||||||||||||||||||||||||
| series b convertible preferred stock, 0.0001 par value; 6,362,658 shares authorized, issued and outstanding at december 31, 2016 and zero shares authorized, issued and outstanding at december 31, 2017 | ||||||||||||||||||||||||||||||||
| series c convertible preferred stock, 0.0001 par value; 26,215,411 shares authorized, issued and outstanding at december 31, 2016 and zero shares authorized, issued and outstanding at december 31, 2017 | ||||||||||||||||||||||||||||||||
| series d convertible preferred stock, 0.0001 par value; 21,099,351 shares authorized, issued and outstanding at december 31, 2016 and zero shares authorized, issued and outstanding at december 31, 2017 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; zero shares authorized, issued and outstanding at december 31, 2016 and 10,000,000 shares authorized, and zero shares issued and outstanding at december 31, 2017 | ||||||||||||||||||||||||||||||||
| series a convertible preferred stock, 0.0001 par value; 2,670,000 shares authorized, issued and outstanding at december 31, 2016 and september 30, 2017; liquidation value of 2,670,000 at september 30, 2017 | 2,654,405 | |||||||||||||||||||||||||||||||
| series b convertible preferred stock, 0.0001 par value; 6,362,658 shares authorized, issued and outstanding at december 31, 2016 and september 30, 2017; liquidation value of 6,998,924 at september 30, 2017 | 6,944,148 | |||||||||||||||||||||||||||||||
| series c convertible preferred stock, 0.0001 par value; 26,215,411 shares authorized, issued and outstanding at december 31, 2016 and september 30, 2017; liquidation value of 32,769,264 at september 30, 2017 | 35,542,707 | |||||||||||||||||||||||||||||||
| series d convertible preferred stock, 0.0001 par value; 21,099,351 shares authorized, issued and outstanding at december 31, 2016 and september 30, 2017; liquidation value of 47,135,950 at september 30, 2017 | 46,913,666 | |||||||||||||||||||||||||||||||
| series e convertible preferred stock, 0.0001 par value; no shares authorized, issued and outstanding at december 31, 2016; 23,376,108 share authorized at september 30, 2017; 7,792,035 issued and outstanding at september 30, 2017; liquidation value of 20,033,322 at september 30, 2017 | 19,747,847 |
We provide you with 20 years of balance sheets for Apellis Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Apellis Pharmaceuticals. Explore the full financial landscape of Apellis Pharmaceuticals stock with our expertly curated balance sheets.
The information provided in this report about Apellis Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.